Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria

Neuropsychopharmacology

Volumn 20, Issue 6, 1999, Pages 582-590

  Bartzokis, George ^a,b,c   Beckson, Mace ^c,d   Newton, Thomas ^c,d   Mandelkern, Mark ^c,e   Mintz, Jim ^c,d   Foster, Jennifer A ^c   Ling, Walter ^c,d   Bridge, T Peter ^f  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Amygdala; Cocaine; Euphoria; Hippocampus; MRI; PET; Selegiline

Indexed keywords

COCAINE; FLUORODEOXYGLUCOSE F 18; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DEPENDENCE; EUPHORIA; FEMALE; GLUCOSE UTILIZATION; HIPPOCAMPUS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE; THALAMUS;

ADULT; AMYGDALA; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; EUPHORIA; FEMALE; GLUCOSE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; TEMPORAL LOBE; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033151283     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00092-X     Document Type: Article

References (43)

1. Aggleton J.P. The functional effects of amygdala lesions in humans. A comparison with findings from monkeys Aggleton J.P. The Amygdala. Neurobiological Aspects of Emotions, Memory, and Mental Dysfunction:1992;485-504 Wiley, New York.
2. Bartzokis G., Mintz J., Marx P., Osborn D., Gutkind D., Chiang F., Phelan C.K., Marder S.R. Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. Magn Reson Imaging. 11:1993;993-1006.
3. Bartzokis G., Mintz J., Sultzer D., Marx P., Herzberg J., Phelan C., Marder S. In vivo MR evaluation of age-related increases in brain iron. AJNR. 15:1994;1129-1138.
4. Bechara A., Tranel D., Damasio H., Adolphs R., Rockland C., Damasio A.R. Double dissociation of conditioning and declarative knowledge relative to amygdala and hippocampus in humans. Science. 269:1995;1115-1118.
5. Berger S.P., Hall S., Mickalian J.D., Reid M.S., Crawford C.A., Delucchi K., Carr K. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 347:1996;504-508.
6. Blaine J.D., Ling W. Psychopharmacologic treatment of cocaine dependence. Psychopharmacol Bull. 28:1992;11-14.
7. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron. 19:1997;591-611.
8. Bridge TP, Weinreib R, Batki S, Bartzokis G, Li S-H, Hill J (1997): Selegiline treatment for cocaine dependence. Proceedings of American College of Neuropsychopharmacology 36th Annual Meeting. Scientific Abstracts, 207.
9. Childress A.R., Mozley P.D., Fitzgerald J., Reivich M., Jaggy J., O'Brien C.P. Regional brain flow during cue-induced cocaine craving. NIDA Research Monograph. 162:1995;194.
10. Gaffan D. Amygdala and the memory of reward. Aggleton J.P. The Amygdala. Neurobiological Aspects of Emotions, Memory, and Mental Dysfunction:1992;Wiley-Liss, New York.
11. Gerlach M., Youdim M.B.H., Riederer P. Pharmacology of selegiline. Neurology. 47:1996;S137-S145.
12. Golwyn D.H. Cocaine abuse treated with phenelzine. Int J Addict. 23:1988;897-905.
13. Grant S., London E.D., Newlin D.B., Villemagne V.L., Liu X., Contoreggi C., Phillips R.L., Kimes A.S., Margolin A. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA. 93:1996;12040-12045.
14. Haberny K.A., Walsh S.L., Ginn D.H., Wilkins J.N., Garner J.E., Setoda D., Bigelow G.E. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. 39:1995;55-62.
15. Hsu K.S., Huang C.C., Su M.T., Tsai J.J. L-deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism. J Pharmacol Exper Therapeut. 279:1996;740-747.
16. Imperato A., Obinu M.C., Gessa G.L. Stimulation of both D1 and D2 receptors facilitates in vivo acetocholine release in the hippocampus. Brain Res. 618:1993;341-345. a.
17. Imperato A., Obinu M.C., Gessa G.L. Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus. Eur J Pharmacol. 238:1993;377-381. b.
18. Imperato A., Obinu M.C., Casu M.A., Mascia M.S., Carta G., Gessa G.L. Chronic morphine increases hippocampal acetylcholine release. Possible relevance in drug dependence Eur J Pharmacol. 302:1996;21-26.
19. Knoll J., Miklya I., Knoll B., Marko R., Kelemen K. Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci. 58:1996;817-827.
20. Koob G.F., Weiss F. Neuropharmacology of cocaine and ethanol dependence. Galanter M. Recent Developments in Alcoholism, vol. 10. 1992;Plenum Press, New York.
21. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D. SAS System for Mixed Models. 1996;SAS Institute, Inc, Cary, NC. p 633.
22. London E.D., Cascella N.G., Wong D.F., Philips R.L., Dannals R.F., Links J.M., Herning R., Grayson R., Jaffe J.H., Wagner H.N. Jr. Cocaine-induced reduction of glucose utilization in human brain. Arch Gen Psychiat. 47:1990;567-574.
23. Lyons D., Freidman D.P., Nadar M.A., Porrino L.J. Cocaine alters cerebral metabolism within the ventral striatum and limbic cortex of monkeys. J Neurosci. 16:1996;1230-1238.
24. Madras B.K., Kaufman M.J. Cocaine accumulates in dopamine-rich regions of primate brain after I.V. administration. Comparison with mazindol distribution Synapse. 18:1994;261-275.
25. Morgan M.J., Cascella N.G., Stapleton J.M., Phillips R.L., Yung B.C.K., Wong D.F., Shaya E.K., London E.D. Sensitivity to subjective effects of cocaine in drug abusers. Relationship to cerebral ventricle size Am J Psychiat. 150:1993;1712-1717.
26. Nishijo H., Ono T., Nishino H. Single neuron responses in amygdala of alert monkey during complex sensory stimulation with affective significance. J Neurosci. 10:1988;3570-3583.
27. O'Brien C.P., Volpicelli L.A., Volpicelli J.R. Naltrexone in the treatment of alcoholism. A clinical review Alcohol. 13:1996;35-39.
28. Paterson I.A., Davis B.A., Durden D.A., Juorio A.V., Yu P.H., Ivy G., Milgram W., Mendonca A., Wu P., Boulton A.A. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the Macaque (Macaca facicularis) brain. Neurochem Res. 20:1995;1503-1510.
29. Pearson G.D., Jeffery P.J., Harris G.J., Ross C.A., Fischman M.W., Camargo E.E. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiat. 150:1993;495-497.
30. Pontieri F.E., Mainero C., La Riccia M., Passarelli F., Orzi F. Functional correlates of repeated administration of cocaine and apomorphine in the rat. Eur J Pharmacol. 284:1995;205-209.
31. Rothman R.B. Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine. A preliminary case series (letter) J Sub Abuse Treatm. 12:1995;449-453.
32. Rothman R.B., Ayestas M., Baumann M.H. Phentermine pretreatment antagonizes the cocaine-induced rise in mesolimbic dopamine. Neuroreport. 8:1996;7-9.
33. Satel S.L., Krystal J.H., Delgado P.L., Kosten T.R., Charney D.S. Tryptophan depletion and attenuation of cue-induced craving for cocaine. Am J Psychiat. 152:1995;778-783.
34. Schneider L.S., Tariot P.N., Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Therapeut. 56:1994;750-756.
35. Schultz W., Apicella P., Ljungberg T., Romo R., Scarnati E. Reward-related activity in the monkey striatum and substantia nigra. Prog Brain Res. 99:1993;227-235.
36. Stein E.A., Fuller S.A. Cocaine's time action profile on regional cerebral blood flow in the rat. Brain Res. 626:1993;117-126.
37. Tutton C.S., Crayton J.W. Current pharmacotherapies for cocaine abuse. A review J Addict Dis. 12:1993;109-127.
38. Volkow N.D., Fowler J.S., Wolf A.P., Hitzemann R., Dewey S., Bendriem B., Alpert R., Hoff A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiat. 148:1991;621-626.
39. Volpicelli J.R., Watson N.T., King A.C., Sherman C.E., O'Brien C.P. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiat. 152:1995;613-615.
40. White N.M. Addictive drugs as reinforcers. Multiple partial actions on memory systems Addiction. 91:1996;921-949.
41. Whitelaw R.B., Markou A., Robbins T.W., Everitt B.J. Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology. 127:1996;213-224.
42. Wilson J.M., Nobrega J.N., Corrigall W.A., Coen K.M., Shannak K., Kish S.J. Amygdala dopamine levels are markedly elevated after self- but not passive-administration of cocaine. Brain Res. 668:1994;39-45.
43. Wise R.A. Neurobiology of addiction. Curr Opinion Neurobiol. 6:1996;243-251.